News

San Francisco, CA - Tasman Therapeutics, a biotechnology company developing novel treatments for patients with hard-to-treat mood disorders, announced today that CEO Dan Browne will participate in a panel entitled “Reimagining Ketamine Delivery for Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 3:30pm ET.

The panel will examine how formulation technology expands patient care and improves outcomes outside a clinical setting through safe, rapid and durable antidepressant efficacy. 

These can be derived without disassociation by oral administration of a proprietary racemic ketamine-based psychedelic therapy such as R-107, Tasman Therapeutics’ bioengineered oral controlled tablet technology.

The webcast will be live on Monday April 27, 2026, at 3:30 pm ET. To access the live webcast, please visit:
https://event.summitcast.com/view/HTrbmKNKd3jrHMB6knVrhU/ntYs3e8wNeU97tmBhqXwRa

An archived version of the webcast will be available for at least 30 days following the presentation.

About Tasman Therapeutics

Tasman Therapeutics, Inc. is a US affiliate of New Zealand-based Douglas Pharmaceuticals Ltd with a pipeline developing novel treatments for mood disorders. The most advanced asset is R-107, a proprietary Phase 3 ready ketamine oral dose as a therapy for patients with hard-to-treat depression. We routinely post information that may be important to investors on our website at www.tasmantherapeutics.com. Follow us on LinkedIn.

Contact

Dan Browne
CEO
Tasman Therapeutics
DanB@tasmantherapeutics.com